help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suri, R.
Right arrow Articles by Shute, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suri, R.
Right arrow Articles by Shute, J. K.
American Journal of Respiratory and Critical Care Medicine Vol 166. pp. 352-355, (2002)
© 2002 American Thoracic Society


Original Article

Effects of Recombinant Human DNase and Hypertonic Saline on Airway Inflammation in Children with Cystic Fibrosis

Ranjan Suri, Lindsay J. Marshall, Colin Wallis, Christopher Metcalfe, Andrew Bush and Janis K. Shute

Department of Respiratory Paediatrics, Royal Brompton Hospital, London; Respiratory Unit, Great Ormond Street Hospital, London; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth; and Medical Research Council Biostatistics Unit, Institute of Public Health, Cambridge, United Kingdom

Correspondence and requests for reprints should be addressed to Dr. Ranjan Suri, MRCPCH, Department of Respiratory Paediatrics, Royal Brompton and Harefield NHS Trust, Sydney Street, London SW3 6NP, UK. E-mail: suriranjan{at}hotmail.com

Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis (CF), but it may liberate cationic mediators bound to DNA in the airways. An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutrophilic inflammation. We compared the effect of rhDNase and HS on cationic proinflammatory mediators in CF sputum. In a randomized, crossover trial, 48 children with CF were allocated consecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS. Sputum levels of total interleukin-8 (IL-8), free IL-8, myeloperoxidase, eosinophil cationic protein, and neutrophil elastase (NE) activity were measured before and after each treatment. The change in mediator levels from baseline with daily rhDNase and HS was not significant; however, with alternate-day rhDNase, there was an increase in free IL-8. When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected. Only changes in NE activity were associated with changes in lung function. In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.

Key Words: cystic fibrosis • inflammation • rhDNase • saline




This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
M. Alipour, Z. E. Suntres, and A. Omri
Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa
J. Antimicrob. Chemother., May 22, 2009; (2009) dkp165v1.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
S. D. Sagel, J. F. Chmiel, and M. W. Konstan
Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
Proceedings of the ATS, August 1, 2007; 4(4): 406 - 417.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. van der Vaart, D. S. Postma, W. Timens, H. F. Kauffman, M. N. Hylkema, and N. H.T. ten Hacken
Repeated sputum inductions induce a transient neutrophilic and eosinophilic response.
Chest, October 1, 2006; 130(4): 1157 - 1164.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. J. Serisier, J. K. Shute, P. M. Hockey, B. Higgins, J. Conway, and M. P. Carroll
Inhaled heparin in cystic fibrosis
Eur. Respir. J., February 1, 2006; 27(2): 354 - 358.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. G. O'Riordan, L. B. Seischab, Q.-L. Ying, E. Colon-Carreras, B. Chughtari, L. B. Palmer, and S. R. Simon
Antiprotease Function of Airway Secretions in Purulent Tracheobronchitis
Chest, November 1, 2005; 128(5): 3167 - 3176.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. van der Vaart, G. H. Koeter, D. S. Postma, H. F. Kauffman, and N. H. T. ten Hacken
First Study of Infliximab Treatment in Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 465 - 469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 333 - 344.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society
  Red Transition